Targeting Triple-negative Breast Cancer
The FDA approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer.
Progress Against Cancer
The FDA approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer.
The FDA has approved a new molecularly targeted therapeutic for treating certain patients with advanced or metastatic HER2-positive breast cancer.
A study shows that antibiotic use prior to starting immunotherapy for melanoma is associated with decreased survival and other cancer news of the week from the staff of Cancer Today.
The first molecularly targeted therapeutic for use in the treatment of bile duct cancer has been approved by the FDA.
Treating a rare cancer with a chemotherapy gel.
A new study suggests that a HER2-targeted therapy approved for breast cancer may be effective for several other cancers. Human epidermal growth factor receptor 2 (HER2) is a protein that can promote cancer progression...
Responding to the coronavirus, cancer patient advocates and nonprofits expand existing outreach initiatives and launch new ones.
Young adults with a history of cancer are more likely to try e-cigarettes than their peers, and more news of the week from Cancer Today.
A new study finds that Latina women with a higher proportion of Indigenous American ancestry may be at increased risk of being diagnosed with HER2-positive breast cancer.
The first allogeneic hematopoietic-cell transplant (HCT) – a complex procedure where a patient receives blood stem cells isolated from a healthy donor – was performed in 1957. Now, over 9,000 allogeneic hematopoietic-cell transplants are performed per year in the United States. This type of transplant is generally used to treat patients with bone marrow disorders, including certain types of leukemia, lymphoma, and multiple myeloma.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More